

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 December 2000 (21.12.2000)

PCT

(10) International Publication Number
WO 00/76479 A1

(51) International Patent Classification⁷: A61K 9/16,
9/22, 47/30

(74) Common Representative: RANBAXY LABORATORIES LIMITED; Jayadeep R. Deshmukh, 600 College Road East, Suite 2100, Princeton, NJ 08540 (US).

(21) International Application Number: PCT/IB00/00765

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 7 June 2000 (07.06.2000)

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

Published:

(26) Publication Language: English

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

(30) Priority Data:
867/DEL/99 11 June 1999 (11.06.1999) IN
09/587.535 5 June 2000 (05.06.2000) US

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (*for all designated States except US*): RANBAXY LABORATORIES LIMITED [IN/IN]; 19 Nehru Place, New Delhi 110 019 (IN).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): MUKHERJI, Gour [IN/IN]; E-12/31, Phase - 1, DLF Qutab Enclave, Gurgaon 122 001, Haryana (IN). GOEL, Sandhya [IN/IN]; C-517, Saraswati Vihar, Delhi 110 034 (IN). ARORA, Vinod, Kumar [IN/IN]; 20-B, DG-II, Vikas Puri, New Delhi 110 018 (IN).

WO 00/76479 A1

(54) Title: TASTE MASKED COMPOSITIONS

(57) Abstract: A taste masked composition which comprises a bitter tasting drug, a combination of two enteric polymers comprising, a methacrylic acid copolymer and a phthalate polymer is described. The composition of the present invention is prepared by dissolving the active ingredient, the methacrylic acid copolymer and the phthalate polymer in a solvent and recovering the composition from the solution thereof.

TASTE MASKED COMPOSITIONS

FIELD OF INVENTION

The present invention relates to taste masked compositions for bitter drugs, comprising a combination of two enteric polymers, such as a methacrylic acid copolymer, and a phthalate polymer. It also relates to a process 5 for preparing such a composition.

BACKGROUND OF THE INVENTION

For ease and safety of administration, most drugs are formulated as tablets or capsules for oral administration. However, patients at the extremes 10 of age, such as children and the elderly, often experience difficulty in swallowing solid oral dosage forms. For these patients, drugs are commonly provided in liquid dosage forms such as solutions, emulsions and suspensions. These dosage forms usually permit perceptible exposure of the active drug ingredient to the taste buds, which can be a problem when the drugs have an 15 unpleasant taste or are extremely bitter. Conventional taste masking techniques such as the use of sweeteners, amino acids and flavoring agents are often unsuccessful in masking the taste of highly bitter drugs and other techniques have been and continue to be exploited for the effective taste masking 20 of such drugs. Extremely bitter drugs, like, quinine, ciprofloxacin, clarithromycin, cefuroxime axetil, can now be formulated as a fairly acceptable range of products even for pediatric use, which through conventional techniques would be impossible to formulate.

Use of cation - exchange resins (such as polysulfonic acid and polycarboxylic acid polymers) to adsorb amine drugs for taste masking and sustained release has been reported to have limited applicability and is not capable of masking the taste of highly bitter drugs. Coating of bitter drugs is
5 another method which has been reported for taste masking. This technique alone may prove effective for moderately bitter drugs or in products where the coated particles are formulated as aqueous preparations before administra-
tion or are formulated in a non-aqueous medium. This technique has its limitations as coating of fine particles is usually technology intensive and
10 coated granules are readily ruptured by chewing and compression.

Lipid-based microencapsulation is another technique used to taste mask the drugs. This technique requires highly sophisticated hot-melt granu-
lation for producing fine particles, and may have adverse effects on heat sensitive molecules or restrict drug release adversely. U.S. Patent No.
15 4,865,851 describes cefuroxime axetil in particulate form coated with an integral coating of lipid or a mixture of lipids.

U.S. Patent No. 4,808,411 describes a taste-masked composition comprising 95% of erythromycin or a derivative thereof and about 5 to about 75% of a carbomer. The drug and carbomer are believed to be held together
20 by both the ionic interactions between the amine group of erythromycin compound and the carbonyl group of the carbomer and by the gel properties of the carbomer. This complex is further taste masked by coating. Although use of this complexing technique, optionally with a coating, has evolved into a

useful technique for taste-masking, proper selection of the complexing agent is vital such that in trying to achieve taste-masking, drug release is not compromised.

U.S. Patent No. 5,286,489 describes a porous drug-polymer matrix formed by admixing one or more bitter tasting active ingredient and a methyl methacrylic ester copolymer in at least a 1:1 by weight ratio of active ingredient to copolymer, effective to mask the taste of the drug. None of the examples described in this patent disclose the effect of these polymers on the release of the drug from the matrix. It has been our experience that although the drug-polymer matrix formed following the teachings of this patent results in good taste-masking, it also retards the rate of drug release from the matrix to an extent which would be unacceptable for a conventional immediate release formulation. Following the teachings of this patent, only 42% of cefuroxime axetil was released from the matrix in 45 minutes in media of pH greater than 4.0. The matrix described in this patent is therefore unsuitable for drugs which are absorbed at a pH range greater than 4.0. To enhance the release of the drug, an enteric phthalate polymer was added into the matrix without significantly compromising on the taste masking.

Accordingly, none of the references heretofore described is completely satisfactory for various reasons.

SUMMARY OF THE INVENTION

The object of the present invention is to provide a taste masked composition, which effectively masks the taste of the drug without compromising the dissolution rate, comprising a bitter tasting drug and a combination of 5 two enteric polymers comprising a methacrylic acid copolymer and a phthalate polymer.

A further object of the present invention is to describe a process for the preparation of a taste masked matrix comprising the process of dissolving the bitter tasting drug, a methacrylic acid copolymer and a phthalate polymer, in a 10 suitable organic solvent followed by the recovery of said taste masked matrix from the solution thereof.

DETAILED DESCRIPTION OF THE INVENTION

The taste masked composition of the present invention comprises a bitter tasting active, and two enteric polymers wherein the enteric polymers 15 are a methacrylic acid copolymer and a phthalate polymer. Examples of bitter or unpleasant tasting drugs which may be used, include, but are not limited to, macrolide antibiotics, such as erythromycin and clarithromycin, fluoroquinolones such as ciprofloxacin and norfloxacin, cephalosporins such as cefuroxime and ceftriaxone, tetracyclic antibiotics like chloramphenicol, chlorpromazine etc. The drug itself or its pharmaceutically acceptable salt or ester may 20 be used in the present invention.

The methacrylic acid copolymers used according to the present invention, may include methylmethacrylic ester copolymers, such as Eudragit S and Eudragit L (trademark of Rohm Pharma) and copolymers of ethyl acrylate and methacrylic acid as Eudragit L-100-55 (trademark of Rohm Pharma). The phthalate polymers include cellulose acetate phthalate, ethyl vinyl phthalate, polyvinyl acetate phthalate and hydroxy alkyl cellulose phthalates. This combination of the two enteric polymers, methacrylic acid copolymer and a phthalate polymer results in optimal taste-masking and dissolution characteristics of the drug. The ratio of methacrylic acid copolymer to phthalate polymer can be varied from 1:9 to 9:1 depending upon intensity of bitterness and desired release of the active ingredient. Most preferably the two polymers are in the ratio of 1:1.

Preferably for optimal taste masking effect, total polymer to drug ratio is at least 1:4.

According to the present invention, the taste masked matrix described above, is prepared by dissolving, optionally with heating, the bitter active ingredient, a methacrylic acid copolymer and a phthalate polymer in a solvent system and then recovering the matrix including the active ingredient and the two polymers from the solution thereof. The solvent system chosen is one in which, both the active ingredient and the polymers are either soluble or swellable. Preferred solvents include water, ketones such as acetone, alcohols such as ethanol, esters such as ethyl acetate and their mixtures. The matrix is recovered by conventional methods which include vacuum

evaporation, tray drying, spray drying, and drum or belt film drying. Spray drying is the preferred method for solvent removal. The "solid solutions" thus formed keep the drug in a finely dispersed state within the polymers, preventing the exposure of the bitter tasting drug to the taste buds.

5 The process of spray drying gives highly porous material which can be further compacted to granules to improve the taste masking effect. The porosity of the granules thus obtained, is not only important for dissolution but also determines the extent of taste masking.

10 Channeling agents can be used to further tailor the drug release from the compacted granules. Channeling agents help in opening up the granules in a specific media as desired. The channeling agents include, disintegrants like croscarmellose sodium, crospovidone and sodium starch glycolate, diluents such as lactose, mannitol, sodium chloride, talc, polyvinyl pyrrolidone; gelling agents like carbopol, and xanthan gum, among others.

15 The taste masked granules obtained may be mixed with flavoring agents such as natural or artificial flavors, citric and tartaric acids, sweeteners such as saccharin and aspartame, and with other pharmaceutically acceptable excipients to be formulated as conventional whole, chewable or dispersible tablets, dry syrups, suspensions, sachets or any other suitable oral
20 dosage forms.

The use of particle coating offers additional taste masking on the product. The coating composition can be constituted of either pH dependent

or pH independent polymers depending on desired product characteristics. Coating compositions such as that described in our PCT application No. PCT/IB99/01735 (which is incorporated herein by reference) offer additional advantages as they can effectively mask the remaining bitterness of the drug
5 without significantly affecting its dissolution profile. Other coating polymers such as the cellulosic polymers and methacrylic acid copolymers may also be used to optimize the taste masking effect.

The examples given herein further illustrate the effectiveness of our formulation in achieving both taste-masking and optimal dissolution of the
10 drug from the matrix.

Example 1

2 g of cefuroxime axetil was taken together with 2 g polymer mixture (0.7: 0.3, Eudragit L100-55: hydroxypropyl methyl cellulose phthalate) and dissolved in acetone (20 ml) containing 5% water. The resulting mixture was
15 tray dried and sized to obtain BSS mesh 44/85 particles. These granules showed adequate taste masking and 95% of the drug was released from the matrix within 45 minutes in pH 6.8 phosphate buffer.

Example 2

20 g cefuroxime axetil and 40 g total polymer (1.2:0.8 w/w mixture of Eudragit L-100-55 and hydroxypropyl methyl cellulose phthalate) were dissolved in 112ml acetone and 16 ml water mixture. The solvent was

removed by tray drying under vacuum at 40°C for 12 hours. The dried mass was milled to get a BSS mesh 44/85 size fraction. The granules thus obtained showed adequate taste masking and released 100% of the drug in 45 minutes in pH 6.8 phosphate buffer.

5

Example 3

60 g cefuroxime axetil and 60 g total polymer (1:1 w/w mixture of Eudragit L-100-55 and hydroxypropyl methyl cellulose phthalate) were dissolved under stirring in a mixture of 875 ml acetone and 125 ml water at 35-40°C. The solvent was removed by spray drying. The spray dried material 10 was further dried for 12 hours at 40°C under vacuum to obtain a fluffy and amorphous material. This spray dried material was compacted and milled to obtain granules of the desired particle size and taste (BSS mesh 44/85). The granules thus obtained released 100% of the drug from the matrix within 45 minutes in pH 6.8 buffer. These granules therefore showed ideal 15 characteristics of both taste masking and drug release from the matrix.

Example 4

75 g clarithromycin and 75 g polymer (1:1 mixture of hydroxypropyl methyl cellulose phthalate + Eudragit L-100-55) were dissolved under stirring in a mixture of acetone (110ml) and water (15ml) at 45-50°C. The solvent 20 was removed on Buchi rotavapor and the thick viscous mass so obtained was tray dried at 60°C to obtain a flaky, partially taste masked material. The

product thus obtained was milled to give partially taste masked granules of the desired particle size (BSS mesh 44/85).

These granules were further coated with the coating composition described in our PCT application (PCT/IB99/01735) to yield a bitterless material suitable for use in an oral suspension. These coated granules released 84% of the drug within 60 minutes in pH 6.8 phosphate buffer.

CLAIMS:

1. A taste masked composition comprising a bitter tasting drug and a combination of two enteric polymers comprising, a methacrylic acid copolymer and a phthalate polymer.
2. The composition as described in claim 1 wherein the bitter tasting drug is selected from the group consisting of macrolide antibiotics, fluoroquinolones and cephalosporins.
3. The composition as described in claims 1 and 2 wherein the bitter tasting drug is selected from the group consisting of erythromycin, clarithromycin, ciprofloxacin, norfloxacin, cefuroxime, ceftriaxone, chloramphenicol, chloropromazine, and their pharmaceutically acceptable salts and esters.
4. The composition as described in claim 1 wherein the methacrylic acid copolymer is selected from the group consisting of methylmethacrylic ester copolymers and copolymers of ethyl acrylate and methacrylic acid.
5. The composition as described in claim 1 wherein the phthalate polymer is selected from the group consisting of cellulose acetate phthalate, ethylvinyl phthalate, polyvinyl acetate phthalate and hydroxy alkyl cellulose phthalate.
6. The composition as described in claim 1 wherein the ratio of methacrylic acid copolymer to phthalate polymer is between 1:9 or 9:1.

7. The composition as described in claim 1 wherein the combined w/w ratio of the polymers to the drug is at least 1:4.
8. The composition as described in claim 1 wherein the composition is in granular form.
9. The composition of claim 8 wherein the granules include channelling agents selected from the group consisting of croscarmellose sodium, crospovidone, sodium starch glycolate, lactose, mannitol, sodium chloride, talc, polyvinyl pyrrolidone, carbopol, and xanthan gum.
10. The composition of claim 9 wherein the granules are coated.
11. The composition of claims 9 and 10 wherein the granules are mixed with sugar or artificial sweeteners and/or flavoring agents.
12. The composition of claim 9 wherein the taste masked granules are formulated as dry syrups, suspensions, conventional whole, chewable, dispersible tablets or any other suitable oral dosage form.
13. A taste masked composition comprising a bitter tasting drug, methyl methacrylic ester copolymer, and hydroxypropyl methyl cellulose phthalate.
14. A process for the preparation of a taste masked matrix comprising dissolving the bitter tasting drug, a methacrylic acid copolymer and phthalate polymer in a suitable organic solvent and recovering said taste masked matrix from the solution thereof.

15. The process of claim 14 wherein the dissolving happens in the presence of water.
16. A process as described in claim 14 wherein the bitter tasting drug is chosen from the group consisting of macrolide antibiotics, fluoroquinolones and cephalosporins.
17. The process of claim 14 wherein the bitter tasting drug is selected from the group consisting of erythromycin, clarithromycin, ciprofloxacin, norfloxacin, cefuroxime, ceftriaxone, chloramphenicol, chloropromazine, and their pharmaceutically acceptable salts and esters.
18. The process of claim 14 wherein the methacrylic acid copolymer is selected from the group consisting of methyl methacrylic ester copolymers and copolymers of ethyl acrylate and methacrylic acid.
19. The process of claim 14 wherein the phthalate polymer is selected from the group consisting of cellulose acetate phthalate, ethylvinyl phthalate, polyvinyl acetate phthalate and hydroxy alkyl cellulose phthalate.
20. The process of claim 14 wherein the ratio of methacrylic acid copolymer to phthalate polymer is between 1:9 to 9:1.
21. The process of claim 14 wherein the combined w/w ratio of two polymers to the drug is at least 1:4.
22. The process of claim 14 wherein the organic solvents used are selected from ketones, alcohols, esters or mixtures thereof with or without water.

23. The process of claim 14 wherein the matrix is recovered by a method, selected from the group consisting of evaporation, vacuum evaporation, tray drying, spray drying, drum and belt film drying.
24. The drying process of claim 22, wherein the dried product is compacted to granules.
25. The process of claim 23 wherein the compacted granules are coated.
26. The process of claim 22 wherein the granules are mixed with sugar or artificial sweeteners and/or flavoring agents.
27. The process of claim 14 wherein the taste masked granules are formulated as dry syrups, suspensions, conventional whole, chewable, or dispersible tablets.
28. A process for the preparation of a taste masked matrix comprising a bitter tasting drug, methyl methacrylic ester copolymer and hydroxypropyl-methylcellulose phthalate wherein the drug and the two polymers are dissolved in acetone, followed by recovery of the said taste masked matrix from the solution thereof.
29. The process of claim 28 comprising cefuroxime axetil, wherein the matrix is recovered by spray drying.
30. The process of claim 28 comprising clarithromycin.

31. A taste masked composition comprising a bitter tasting drug and a combination of two polymers comprising a methacrylic acid copolymer and a phthalate polymer, effective to mask the taste and which release more than 60% of the drug at a pH 6.8 in about an hour.

INTERNATIONAL SEARCH REPORT

International Application No:
PCT/IB 00/00765A. CLASSIFICATION OF SUBJECT MATTER
A61K9/16,A61K9/22,A61K47/30According to International Patent Classification (IPC) or to both national classification and IPC⁷

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98/18454 A1 (EASTMAN CHEMICAL COMPANY) 07 May 1998, abstract, page 6, lines 13-16, claims. --	1, 4-6, 8, 13
X	WO 98/11879 A1 (DEPOMED, INC.) 26 March 1998, abstract, page 4, line 29 - page 5, line 7, claims 1,2,3,7,8,27,29. --	1-5, 8, 13
A	DE 2218147 A (MEIJI SEIKA KAISHA LTD.) 26 October 1972, the whole document. --	1-31
A	US 5175003 A	1-31

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

16 August 2000

Date of mailing of the international search report

10.10.2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

KRENN

INTERNATIONAL SEARCH REPORT

International Application No.

- 2 -

PCT/IB 00/00765

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	(GOLDMAN) 29 December 1992, abstract, claims. --	
A	US 4897270 A (DEUTSCH et al.) 30 January 1990, abstract, column 3, line 3 - column 4, line 10. --	1-31
A	WO 97/16174 A1 (ABBOTT LABORATORIES) 09 May 1997, the whole document. --	1-31
A	VOIGT R.: 'Pharmazeutische Technologie für Studium und Beruf' 1993, ULLSTEIN MOSBY, BERLIN, DE 7th edition, chapter 10.5.1, table 29, chapter 10.6.2.2.- -10.6.2.4. ----	1-31

ANHANG

Zum internationalen Recherchenbericht über die internationale Patentanmeldung Nr.

ANNEX

To the International Search Report to the international Patent Application No.

ANNEXE

Au rapport de recherche international relativ à la demande de brevet international n°

PCT/IB 00/00765 SAE 286927

In diesem Anhang sind die Mitglieder der Patentfamilien der im obengenannten internationalen Recherchenbericht angeführten Patentdokumente angegeben. Diese Angaben dienen nur zur Unterrichtung und erfolgen ohne Gewähr.

This annex lists the patent family members relating to the patent documents cited in the above-mentioned search report. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

La présente annexe indique les membres de la famille de brevets relatifs aux documents de brevets cités dans le rapport de recherche international visée ci-dessus. Les renseignements fournis sont donnés à titre indicatif et n'engagent pas la responsabilité de l'Office.

Im Recherchenbericht angeführte Patentdokumente Patent document cited in search report Document de brevet cité dans le rapport de recherche		Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
WO A1	9818454	07-05-1998	US A 5851579	22-12-1998
WO A1	9811879	26-03-1998	AU A1 44280/97	14-04-1998
			EP A1 941071	15-09-1999
			NO A0 991341	19-03-1999
			NO A 991341	19-05-1999
			US A 5972389	26-10-1999
DE A	2218147	26-10-1972	FR A1 2139825	12-01-1973
DE C2	2218147	18-08-1983	FR B1 2139825	26-12-1975
			GB A 1322306	04-07-1973
			US A 3962419	08-06-1976
US A	5175003	29-12-1992	none	
US A	4897270	30-01-1990	AT A 2609/86	15-01-1991
			AT B 393081	12-08-1991
			AU A1 63232/86	02-04-1987
			AU B2 594082	01-03-1990
			BE A1 905518	30-03-1987
			CA A1 1282331	02-04-1991
			CH A 672736	29-12-1989
			DE A1 3633292	09-04-1987
			DE C0 3677710	04-04-1991
			DK A0 4624/86	29-09-1986
			DK A 4624/86	31-03-1987
			EP A2 223365	27-05-1987
			EP A3 223365	08-06-1988
			EP B1 223365	27-02-1991
			ES AF 2002382	01-08-1988
			FR A1 2591597	19-06-1987
			FR B1 2591597	02-06-1989
			GB A0 8524001	06-11-1985
			GB A0 8623340	05-11-1986
			GB A1 2181052	15-04-1987
			GB B2 2181052	18-10-1989
			GR A 862464	02-02-1987
			HK A 849/90	25-10-1990
			IE B 59089	12-01-1994
			IL A0 80165	31-12-1986
			IL A1 80165	10-06-1991
			IT A0 8648492	29-09-1986
			IT A 1196644	16-11-1988
			JP A2 62123118	04-06-1987
			JP B2 2661662	08-10-1997
			KR B1 9400233	12-01-1994
			LU A 86613	05-04-1988
			NL A 8602466	16-04-1987
			NO A0 863863	29-09-1986
			NO A 863863	31-03-1987
			NO E 173636	04-10-1993
			NO C 173636	12-01-1994
			NZ A 217720	28-07-1988

ANHANG

Zum internationalen Recherchenbericht über die internationale Patentanmeldung Nr.

In diesem Anhang sind die Mitglieder der Patentfamilien der im obengenannten internationalen Recherchenbericht angeführten Patentdokumente angegeben. Diese Angaben dienen nur zur Unterrichtung und erfolgen ohne Gewähr.

ANNEX

To the International Search Report to the International Patent Application No.

PCT/IB 00/00765 SAE 286927

This annex lists the patent family members relating to the patent documents cited in the above-mentioned search report. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

ANNEXE

Au rapport de recherche international relativ à la demande de brevet international n°

La présente annexe indique les membres de la famille de brevets relatifs aux documents de brevets cités dans le rapport de recherche international visée ci-dessus. Les renseignements fournis sont donnés à titre indicatif et n'engagent pas la responsabilité de l'Office.

Im Recherchenbericht angeführte Patentdokumente Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
WO A1 9716174	09-05-1997	PH A 25702	18-09-1991
		PT A 83459	01-10-1986
		PT B 83459	12-05-1989
		SE A0 8604114	29-09-1986
		SE A 8604114	31-03-1987
		SG A 690/90	26-10-1990
		ZA A 8607318	27-05-1987
		AU A1 75176/96	22-05-1997
		AU B2 706837	24-06-1999
		CA AA 2235607	09-05-1997
		EP A1 858324	19-08-1998
		IL A0 123571	30-10-1998
		JP T2 11514646	14-12-1999
		US A 5919489	06-07-1999

THIS PAGE BLANK (USPTO)